EN | FR
EN | FR
Search
Pulmonary,Disease,Treatment,And,Lung,Transplant,Concept.,Human,Hands,Holding

Validating The BLEO-Induced Mouse Model For Drug Discovery

Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by progressive scarring of the lungs, which severely impairs lung function over time. Developing effective treatments for IPF has been a challenge for the medical community, as the mechanisms driving this disease are complex and not fully understood. To accelerate drug discovery, animal models that closely mimic the human disease are crucial. In this context, a recent study by Petersen et al (2024) has made significant strides in validating a well-known IPF mouse model of bleomycin (BLEO) induced Pulmonary Fibrosis and demonstrating its effectiveness in evaluating potential therapies, particularly through the use of advanced lung function testing systems like the vivoFlow and flexiVent.

BLEO-Induced Mouse Model: A Standard in IPF Research

The study focused on the BLEO-induced mouse model of IPF, a widely used tool in preclinical research for understanding IPF progression and evaluating new drug candidates. By administering a single dose of BLEO to male mice, researchers could replicate the functional, biochemical, and histological hallmarks of human IPF, including lung tissue scarring and inflammation.

To ensure the model’s validity for drug testing, researchers used advanced lung function measurement techniques, such as unrestrained whole-body plethysmography (vivoFlow system) along with lung capacities and spirometry (flexiVent system), which confirmed the progressive decline in lung function typical of IPF.

vivoFlow Whole Body Plethysmography 

This study utilized the vivoFlow Whole Body Plethysmography system to non-invasively measure lung function in conscious, unrestrained mice. By placing each mouse in a sealed chamber, the system tracked breathing patterns, including respiratory rate and tidal volume, at multiple time points following BLEO administration. This allowed real-time monitoring of lung dysfunction and fibrosis progression. The technology’s ability to assess lung function without anesthesia or restraint ensured natural respiratory parameters, making it especially useful for selecting mice with impaired lung function for treatment with a TGFβR1/ALK5 inhibitor, improving the accuracy of the model and results.

flexiVent: Precision Lung Function Testing

While vivoFlow provided overall lung function insights, the flexiVent system was used for precise measurements of lung mechanics at the study’s endpoint. Widely regarded as the gold standard for invasive pulmonary function testing, flexiVent allowed controlled mechanical ventilation to assess lung volume, airway resistance, and compliance with exceptional accuracy. In BLEO-treated mice, spirometry tests such as forced vital capacity (FVC) and forced expiratory volume (FEV0.1) revealed reduced lung compliance and inspiratory capacity, confirming lung tissue stiffness and scarring typical of IPF. The system also generated pressure-volume loops to quantify lung damage severity.

The Role of ALK5 Inhibition in IPF Treatment

The study went a step further by investigating the therapeutic potential of a TGFβR1/ALK5 inhibitor (ALK5i), a drug that targets the TGFβ signaling pathway, known to play a key role in the development of fibrosis. Mice treated with ALK5i showed significant improvements in lung function, as measured by both vivoFlow and flexiVent systems. ALK5i reduced fibrotic markers, improved lung capacity, and restored lung elasticity, providing strong evidence of its antifibrotic potential.

The results of this study are particularly exciting because they were consistent across six independent trials, demonstrating the reproducibility of the BLEO-induced IPF mouse model and the reliability of ALK5i as a reference drug for testing future IPF therapies.

Significance of The Study for IPF Drug Discovery

This study emphasizes the critical role of validated, reproducible models in preclinical drug development for idiopathic pulmonary fibrosis (IPF). By utilizing advanced lung function analysis tools, such as vivoFlow and flexiVent, alongside a well-characterized BLEO-induced mouse model, researchers have created a robust platform for evaluating new drug candidates. The vivoFlow system’s ability to monitor lung function in conscious animals throughout the disease course, combined with the precise lung mechanics data provided by flexiVent, allows for a comprehensive assessment of both disease progression and therapeutic efficacy. The study’s findings, particularly with ALK5i treatment, reinforce the BLEO-IPF model as a reliable benchmark for testing antifibrotic therapies, essential for accelerating drug discovery. Looking ahead, expanding the model’s application to female and aged mice and exploring models of sustained fibrosis could further enhance its relevance, bringing us closer to effective IPF treatments.

Featured Products

 Resources

Empowering researchers

Welcome to SCIREQ’s knowledge center. You can find everything from software registration to document downloads to complete list of SCIREQ publications in this section. Everything you need to get the most out of your SCIREQ system.